Olema Oncology
Carlmin Serafin is an experienced professional in clinical supply chain management, with a background in overseeing end-to-end activities for global clinical studies. Carlmin has held various roles in companies such as Olema Oncology and Gilead Sciences, where responsibilities included protocol review, demand and supply planning, label generation, inventory management, and collaboration with key stakeholders. With a Master of Business Administration degree from Golden Gate University and a Bachelor of Science in Information and Computer Science from Philippine Women's University, Carlmin has a strong educational background to complement practical experience in the field.
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.